	Case 3:19-md-02913-WHO Document 4	073 Filed 07	7/21/23	Page 1 of 7
1 2 3 4 5 6 7 8	Neville S. Hedley (SBN 241022) HAMILTON LINCOLN LAW INSTITUTE CENTER FOR CLASS ACTION FAIRNESS 1629 K Street NW, Suite 300 Washington, DC 20006 Voice: 312-342-6008 Email: ned.hedley@hlli.org <i>Attorneys for Objector Reilly Stephens</i> UNITED STATES I NORTHERN DISTRIC			
9				
10	IN RE: JUUL LABS, INC. MARKETING, SALES PRACTICES, AND PRODUCTS LIABILITY	Case No. 19-1	md-02913	3-WHO
11	LITIGATION,	REILLY STEPHENS' RESPONSE TO		
12 13	This Document Relates to: ALL CLASS ACTIONS			ATTHEW MURPHY, ANT, AND MARIANNE
14			Hon	Villiam H. Orrick
15		Courtroom: Date: Time:	2, 17th	Floor 29, 2023
16		Time.	2.001.	171.
17				
18 19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
	Case No. 19-md-02913-WHO IN RE JUUL LABS, INC. MARKETING, SALES PRAC	CTICES, AND PR	RODUCTS	LIABILITY LITIGATION

Case 3:19-md-02913-WHO Document 4073 Filed 07/21/23 Page 2 of 7

1 In accordance with the Preliminary Approval Order (Dkt. 3779 at 12), Objector Reilly Stephens hereby responds to the objection of Matthew Murphy, Cade Beauparlant, and Marianne Savage on behalf of "M." ("PHAI Objectors"). See Dkt. 4062. While Stephens "adopts any objections not inconsistent with [his own]," Dkt. 4063 at 2, what PHAI Objectors propose—a siphoning off \$30 million in direct relief, or 11.8% of the gross settlement, to fund nonprofit research—is so patently unlawful as to merit a disclaiming response. Dkt. 4063 at 1.

The Court must reject PHAI's proposed settlement revision for at least two reasons. First, PHAI 8 Objectors ask this Court to fundamentally alter the terms of the proposed settlement, a power it does not 9 possess. See Evans v. Jeff D., 475 U.S. 717, 726 (1986); Officers for Justice v. Civil Serv. Comm'n of San Francisco, 688 10 F.2d 615, 630 (9th Cir. 1982). Second, cy pres is simply impermissible, unless or until there is no feasible means to directly disburse funds to the class. See Nachshin v. AOL, LLC, 663 F.3d 1034, 1036 (9th Cir. 2011); accord 12 Principles of the Law of Aggregate Litigation § 3.07 (Am. Law Inst. 2010). Because PHAI Objectors propose 13 cy pres at the expense of direct and admittedly feasible payments to class members, their proposal is unlawful 14 and must be rejected.

15 "Neither the district court[s] nor [the appellate] court[s are] empowered to rewrite the settlement agreed 16 upon by the parties." Officers for Justice, 688 F.2d at 630. "[T]he power to approve or reject a settlement 17 negotiated by the parties before trial does not authorize the court to require the parties to accept a settlement to which they have not agreed." Evans, 745 U.S. at 726. Courts "may not delete, modify, or substitute certain 18 19 provisions," Officers for Justice, 688 F.2d at 630, for the "authority to administer a class-action settlement derives 20 from Rule 23," a purely procedural device. Klier v. Elf Atochem N. Am., Inc., 658 F.3d 468, 475 (5th Cir. 2011); 21 Rawa v. Monsanto Co., 934 U.S. F.3d 862, 871 (8th Cir. 2019) ("District courts do not rewrite settlement agreements."). In flagrant disregard of Evans and Officers for Justice, PHAI Objectors ask this Court to take \$30 22 23 million, not from Class Counsel-who seek an exorbitant \$76.5 million fee (see Stephens Obj. (Dkt. 4063))-24 but from the class itself, to finance nonprofit research. See Dkt. 4062 at 1. Simply put, this is not within the 25 power of the Court. Plaintiffs "request that the district court redraft the terms of the agreement to allow for 26 an alternative method of fund distribution." Rawa, 934 F.3d at 871. But the Court is not a legislator on the 27 appropriations committee, and the proposed settlement is not a draft piece of legislation. The Court cannot 28 rearrange the settlement proceeds without overstepping its authority under Rule 23, which "wisely" confines Case No. 19-md-02913-WHO

7

11

Case 3:19-md-02913-WHO Document 4073 Filed 07/21/23 Page 3 of 7

1 the judicial role to approval or disapproval. Evans, 745 U.S. at 726-27. "In short, the settlement must stand or 2 fall as a whole." Officers for Justice, 688 F.2d at 630. If "[a]bsent such a provision [as that proposed], the 3 Settlement is [rendered] unfair, inadequate, and ... unreasonable," Dkt. 4062 at 3, then the Court has but one option: deny final settlement approval. 4

5 But PHAI Objectors' grievance is meritless. Cy pres is a last resort, not a first resort; it cannot lawfully supplant direct class recovery because "[c]lass members are not indifferent to whether funds are distributed to 6 them or cy pres recipients." In re Baby Prods. Antitrust Litig., 708 F.3d 163, 178 (3d Cir. 2013). Cy pres "took the 7 8 judiciary 'to the utmost verge of the law' even before it was applied to class actions." Keepseagle v. Perdue, 856 9 F.3d 1039 (D.C. Cir. 2017) (Brown, J., dissenting) (quoting Jackson v. Phillips, 96 Mass. 539, 574 (Mass. 1867)). PHAI Objectors treat "cy pres" as though it were a dirty word-the term appears not once in their fourteen-10 11 page objection. That's curious, but unsurprising. After all, cy pres "is a very troublesome doctrine," Six (6) 12 Mexican Workers v. Ariz. Citrus Growers, 904 F.2d 1301, 1312 (9th Cir. 1990) (Fernandez, J., concurring), with the potential to generate "conflicts of interest," "incentives for collussion," and "the [] appearance of [judicial] 13 impropriety." In re Google Inc. St. View Elec. Comms. Litig., 21 F.4th 1102, 1123 (9th Cir. 2021) (Bade, J., 14 15 concurring). More fundamentally, there's an "abiding debate about the lawfulness of Article III courts to permit 16 cy pres distributions," Poblano v. Russell Cellular Inc., 2021 U.S. Dist. LEXIS 108796, *5 (M.D. Fla. Jun. 10, 2021), 17 or whether such distrubutions ever count any form of class benefit. See Frank v. Gaos, 139 S. Ct. 1041, 1047 (Thomas, J., dissenting); Baby Prods., 708 F.3d at 173 (describing the "indirect benefit" of cy pres as "at best 18 19 attenuated and at worst illusory").

20 Given the risks, the Ninth Circuit has a "strong preference for distribution to class members instead 21 of cy pres distributions." Reid v. I.C. Sys., 2021 U.S. Dist. LEXIS 166517, *8 (D. Ariz. Sept. 2, 2021); In re Anthem Inc. Data Breach Litig., 327 F.R.D. 299, 333 (N.D. Cal. 2018) (Koh, J.) (describing "the law's general preference 22 23 for cy pres awards to be limited to scenarios where it is not feasible to make further distributions to class 24 members"); see, e.g., Connor v. J.P. Morgan Chase Bank, N.A., 2021 U.S. Dist. LEXIS 65011, *3 (S.D. Cal. Apr. 2, 25 2021) (approving secondary class member distribution even though settlement had provided for *cy pres*); 26 Camberis v. Ocwen Loan Servicing LLC, 2018 U.S. Dist. LEXIS 198108,, at *8 (N.D. Cal. Nov. 20, 2018) (ordering 27 secondary distribution over cy pres, where settlement was silent). This Circuit has wisely confined class cy pres to "unclaimed or non-distributable" funds only. Nachshin, 663 F.3d at 1036 (emphasis added). "[T]he 28 Case No. 19-md-02913-WHO

Case 3:19-md-02913-WHO Document 4073 Filed 07/21/23 Page 4 of 7

settlement should presumptively provide for further distributions to participating class members unless the 2 amounts involved are too small to make individual distributions economically viable or other specific reasons exist that would make such further distributions impossible or unfair." American Law Institute, PRINCIPLES 3 OF THE LAW OF AGGREGATE LITIGATION § 3.07(b). "[A] of pres distribution to a third party of unclaimed 4 settlement funds is permissible only when it is not feasible to make further distributions to class members." 5 Klier, 658 F.3d at 475 (internal quotations omitted). Conversely, cy pres "is not appropriate" where "the 6 settlement is distributable to class members." Hofmann v. Dutch LLC, 317 F.R.D. 566, 578 (S.D. Cal. 2016). 7 Here, the settlement proceeds are neither unclaimed nor non-distributable—this alone takes cy pres off the 8 table. For starters, the settlement proceeds remain to be distributed, and as such, there aren't-nor could there be-any residual or unclaimed dollars. If, after *all* feasible distributions are made, there remain residual funds, then those dollars might become a candidate for *cy pres*, provided the terms of the settlement so permit. While this Circuit has also coutenanced *cy pres* in the context of *cy pres*-exclusive settlements,¹ the present case is selfevidently not cy pres-exclusive. That being so, cy pres is simply off the table.

PHAI Objectors invoke Judge Polster for the propisition that "any settlement ... should ... 'do something meaningful to abate th[e youth vaping crisis]' and reduce its adverse public health impact rather than simply 'moving money around." Dkt. 4062 at 7 (quoting Transcript of Record at 09:15:51 and 09:23:37, In re Nat'l Prescription Opiate Litig., MDL No. 2804, No. 1:17-CV-2804 N. Dist. Ohio (Jan. 9, 2018)). Setting aside that the Sixth Circuit has consistently rebuked that court's reading of the law,² there are two glaring problems with this line of argument. First, PHAI fundamentally misapprehends the core purpose of class

Case No. 19-md-02913-WHO

IN RE JUUL LABS, INC. MARKETING, SALES PRACTICES, AND PRODUCTS LIABILITY LITIGATION

28

1

3

¹ In In re Google Inc. St. View, for example, the class was so large and the vertification process so costly as to render any direct distributions to the class infeasible. 21 F.4th at 1115. Under such circumstances, "the district court [did not] abuse[] its discretion by approving the [exclsuive] use of cy pres payments." Id. Here, however, the proposed settlement agreement correctly provides for direct distributions to class members.

² See, e.g., In re Nat'l Prescription Opiate Litig., 927 F.3d 919, 924, 929, 933 (6th Cir. 2019) (finding abuse of discretion in the district court's efforts to leverage a settlement between the parties); In re Nat'l Prescription Opiate Litig., 956 F.3d 838, 844 (6th Cir. 2020) (issuing writ of mandamus and commenting that "MDLs are not some kind of judicial border country, where the rules are few and the law rarely makes an appearance"); In re Nat'l Prescription Opiate Litig., 976 F.3d 664, 676 (6th Cir. 2020) ("The district court's course of action neither fully satisfied the critical fairness concerns of Rule 23(b)(3), nor respected the important differences between litigation classes and settlement classes.").

Case 3:19-md-02913-WHO Document 4073 Filed 07/21/23 Page 5 of 7

litigation: to make injured class members whole. Rule 23 is a complex joinder device that aggregates real 2 individuals with real claims into a class if certain prerequisites are satisfied. Shady Grove Orthopedic Assocs., P.A., v. Allstate Ins. Co., 559 U.S. 393, 408 (2010) (class action is a "species" of joinder). Counsel's duty to their client 3 class members works hand in glove with the proper role of the judiciary-namely, "provid[ing] relief to claimants, in individual or class actions, who have suffered, or will imminently suffer, actual harm." Tyson Foods Inc. v. Bouaphakeo, 136 S. Ct. 1036, 1053 (2016) (Roberts, J., concurring) (internal quotation omitted).

Simply put, Rule 23 does not authorize the "private attorney general" model of litigation. S. Rep. No. 109-14, at 58-59 (2005); cf. also Alyeska Pipeline Serv. Co. v. Wilderness Soc'y, 421 U.S. 240, 260-69 (1975) (judiciary cannot award fees on non-legislatively sanctioned "private attorney general" model). While PHAI Objectors seek *cy pres* "to address the underlying *public health crisis* that prompted the surge of class actions" and "the public health harms affecting class members," Dkt. 4062 at 4 (emphasis added), Rule 23-a simple "joinder device for the aggregation of multiple pre-existing claims"—does not furnish an appropriate vehicle to do so. Martin H. Redish, WHOLESALE JUSTICE: CONSTITUTIONAL DEMOCRACY AND THE PROBLEM OF THE CLASS ACTION LAWSUIT 154 (2009). Second, the premise of PHAI's objection—namely that cy pres would "reduce [the] adverse public health impact" of JUUL's conduct better than direct payments to class members—is inherently dubious. See generally Russell M. Gold, Compensation's Role in Deterrence, 91 NOTRE DAME L. REV. 1997, 2003 (2016) (arguing that victim compensation "creates more reputational deterrence than other forms of relief, at least in damages class actions").

CONCLUSION

PHAI Objectors ask this Court to transform the proposed settlement by siphoning off \$30 million dollars of direct monetary relief to finance research which might, at best, offer class members some amporphous, indirect benefit down the line. Evans and Officers for Justice plainly deny the Court this power, and even if the Court *could* alter the proposed settlement, it could not do so in the manner PHAI Objectors propose. For the foregoing reasons, the Court must reject PHAI Objectors' proposed settlement structure.

Case No. 19-md-02913-WHO

IN RE JUUL LABS, INC. MARKETING, SALES PRACTICES, AND PRODUCTS LIABILITY LITIGATION

1

	Case 3:19-md-02913-WH	O Document 4073 Filed 07/21/23 Page 6 of 7	
1	Dated: July 21, 2023	Respectfully submitted,	
2		<u>/s/Neville S. Hedley</u>	
3		Neville S. Hedley (SBN 241022) Hamilton Lincoln Law Institute	
4		CENTER FOR CLASS ACTION FAIRNESS 1629 K Street NW, Suite 300	
5		Washington, DC 20006 Voice: 312-342-6008	
6		Email: ned.hedley@hlli.org	
7		Attorneys for Objector Reilly Stephens	
8			
9			
10			
11			
12			
13			
14			
15			
16 17			
17			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
	Case No. 19-md-02913-WHO IN RE JUUL LABS, INC. MARKI	ETING, SALES PRACTICES, AND PRODUCTS LIABILITY LITIGAT	5 ION

	Case 3:19-md-02913-WHO Document 4073 Filed 07/21/23 Page 7 of 7
	PROOF OF SERVICE
	I hereby certify that on this day I electronically filed the foregoing Objection using the CM/ECF fili
stem	thus effectuating service of such filing on all ECF registered attorneys in this case.
	DATED this 21st day of July 2023
	<u>/s/ Neville S. Hedley</u>
	Neville S. Hedley
	Case No. 19-md-02913-WHO 6
-	IN RE JUUL LABS, INC. MARKETING, SALES PRACTICES, AND PRODUCTS LIABILITY LITIGATION